Comparing two chemotherapies for advanced triple-negative breast cancer in Black women
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two chemotherapy drugs to see which works better for Black women of Caribbean or Ghanaian ancestry with metastatic triple-negative breast cancer. It aims to find a more effective treatment for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a Black woman of Jamaican, Barbadian, or Ghanaian ancestry.
- You are 18 years or older.
- You have metastatic triple-negative breast cancer (cancer that has spread and is negative for three common receptors).
- You are physically active enough to do light work (ECOG 0-1).
- You have not had prior chemotherapy for metastatic disease, and you have never had gemcitabine, anthracyclines, or taxanes.
- You agree to provide blood or tissue samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial studies a standard chemotherapy treatment for Nigerian women with triple-negative breast cancer that has not spread widely. It aims to see how well the treatment works and how safe it is.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.